Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From mAbxience S.L.
Five years after striking a biosimilars alliance with Iceland’s Alvotech, Turkish firm Abdi İbrahim – which boasts the country’s “largest biotech pharmaceutical manufacturing facility” – has shaken hands with Spanish developer mAbxience for technology transfer of an undisclosed oncology biosimilar.
A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”
Amneal has raised its 2023 guidance yet again as company performance remained strong across Q3.
Amneal has struck a deal with mAbxience to gain US rights to two denosumab biosimilars referencing the Prolia and Xgeva brands that have annual US sales in excess of $4bn.
- Contract Manufacturing Organization
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- CHEMO Group
- Kevilmare Holding GmbH
- Insud Pharma
- mAbxience S.A
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.